Navigation Links
Chinese Medical Device Market Worth $53.5 billion by 2020 Says a New Research Report at RnRMarketResearch.com
Date:10/23/2013

Dallas, TX (PRWEB) October 24, 2013

The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.

Considerable investment in China’s pharmaceutical Research & Development (R&D) sector, along with numerous government-initiated reforms, will spark soaring growth in the country’s pharmaceutical market in the near future. China is the most populated country in the world. In 2012, its population was approximately 1.3 billion, approximately one fifth of the global population. Growth has however been effectively controlled and has slowed down due to the strict enforcement of family-planning and one-child policies. The decline in the size of the young working-age group and the growing elderly population are however matters of concern for policy planners.

Complete report is available at http://www.rnrmarketresearch.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-china-market-report.html .

According to the company’s latest report on China’s healthcare industry CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – China, the country’s pharmaceutical market value will climb from an estimated $48 billion in 2012 to a massive $315 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 26.5%. This increase will see China’s pharmaceutical market become the second largest in the world, with surging revenue propelling industry value significantly closer to that of the US, which GlobalData forecasts to reach $475 billion in 2020.

An expanding and aging population will also play a key role in boosting China’s pharmaceutical market revenue. With the country’s elderly population expected to account for 19% of its total population of 1.41 billion in 2020, GlobalData expects to see a rising prevalence of chronic diseases, which will in turn spark an increasing demand for treatment. This factor will also be a primary driver behind the rising value of China’s medical device market – the second largest in Asia, behind Japan – which forecasts will climb from $20 billion in 2012 to $54 billion in 2020.

This report identifies the key trends in China’s healthcare market, providing insights into the demographic, regulatory and reimbursement landscape and the country’s healthcare infrastructure, as well as the trends and segmentation of the Chinese pharmaceutical and medical device markets.

Scope

The report provides information on the healthcare, regulatory and reimbursement landscape in China, and includes:

Overview of the pharmaceutical and medical devices markets, comprising market size, segmentation, and key drivers and barriers;

Profiles and SWOT analysis of the major players in the pharmaceutical market, of which the major Multinational Companies (MNCs) were GlaxoSmithKline (GSK), Pfizer, and AstraZeneca; and the major domestic players were Harbin Pharmaceutical Group and Tasly Pharmaceutical Group; and the medical device market, of which the major players were Siemens Healthcare, GE Healthcare, Fresenius Medical Care, GlaxoSmithKline, and Philips Healthcare;

Insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, regulatory agencies, and market authorization processes for new drugs and medical devices;

Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure, and healthcare expenditure;

An overview of the opportunities for and challenges to growth in the Chinese healthcare market.

Reasons to buy

This report will enhance your decision-making capability by allowing you to:

Develop business strategies by understanding the trends shaping and driving China’s healthcare market;

Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical and medical devices market segments, and companies likely to impact the healthcare market in the future;

Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors;

Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investments, and strategic partnerships;

Identify, understand and capitalize on the opportunities and challenges in China’s healthcare market.

Purchase a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=111444.

Browse more reports on Regulation Market: http://www.rnrmarketresearch.com/reports/life-sciences/healthcare/regulation-policy/regulation.

Contact sales(at)rnrmarketresearch(dot)com for further information.

About Us:
RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online database of market research reports that offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/healthcare-regulatory/reimbursement-china/prweb11260851.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Combining Chinese and Western medicine could lead to new cancer treatments
2. Chinese Orthopedic Biomaterials Market
3. Chinese OTC Drug Industry 2013 Analysis and 2017 Forecasts in New Research Report at RnRMarketResearch.com
4. Chinese Contract Research Organization Market (CRO) 2013 Analysis in New Research Report at RnRMarketResearch.com
5. 123Greetings Launched Spanish, Chinese, Russian, & Hindi Ecards Under World Languages, Adding Diversity To Its Collection
6. Chinese Traditional Clothing with Discounts Now Online at 4leafcity.com
7. Chinese CDC and Aeras sign agreement to collaborate on TB vaccine R&D
8. UCLA and Chinese scientists analyze genetic makeup of human and mouse embryos in amazing detail
9. 4leafcity.com Has Launched a Promotional Offer on Chinese Traditional Dresses
10. International Food Protection Training Institute Hosts Chinese Delegation
11. Daily QiGong and Chinese Medicine Improves Health Says Alternative Medicine Pioneer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
(Date:3/27/2017)... ... March 27, 2017 , ... SyncDog, Inc. , the ... partners LG Business Solutions at ATARC Federal Mobile Computing Summit , March ... provide education and examination into the mobility tools and technology employed by the ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the first ... for the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment to ... such as ANSI, ISO and proven test methods used in the field of ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... can quickly sideline athletes. A type of groin injury, it occurs when the ... to serious, intense pain in and around the lower torso, as well as ...
(Date:3/27/2017)... NY (PRWEB) , ... March 27, 2017 , ... ... in epigenetic research products enables researchers to pursue the recent RNA methylation “gold ... methylation . In light of the newfound characteristics of N6-methyladenosine, or m6A ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... ... that adult use in states where cannabis is legal will generate ... $559 million will be from cannabis specific taxes, such as ... remaining $96 million will be earned from state sales taxes that ...
(Date:3/27/2017)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... AGI-134, an immunotherapy for the treatment of multiple cancers, obtained ... featured at the upcoming American Association for Cancer Research ... to be held on April 1-5, 2017. ... An abstract titled ...
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
Breaking Medicine Technology: